Wednesday, 18 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

7:08 AM ET 8-K
Financial Results Old National Bancorp ONB

Old National Bancorp Financial Results

Old National Bancorp reported record third quarter 2026 net income of $250.0 million and diluted EPS of $0.66. The results were driven by record efficiency ratios and growth in both deposits and loans, with total deposits reaching $57.6 billion.

Term
Q3 2026

“With our strong 3rd quarter results, highlighted by record net income, a record efficiency ratio, and growth in both deposits and loans, Old National continues to demonstrate the strength and consistency of our operating model.”

Jim Ryan, Chairman and CEO

“Our disciplined focus on fundamentals continues to drive profitable growth, positive operating leverage, and meaningful value creation for our shareholders.”

Jim Ryan, Chairman and CEO
7:06 AM ET 8-K
Clinical Trial Data Roivant Sciences Ltd. ROIV

Roivant Sciences Clinical Trial Data

Roivant and its subsidiary Priovant Therapeutics announced positive results from the Phase 3 CLARITY program evaluating brepocitinib in non-infectious uveitis (NIU). The drug met its primary and all key secondary endpoints in two identical trials, demonstrating a median time to treatment failure of over 48 weeks compared to 12 weeks for placebo, and the company plans to file a supplemental New Drug Application (sNDA) in the first half of 2027.

7:05 AM ET 8-K
Financial Results Philip Morris International Inc. PM

Philip Morris International Financial Results

Philip Morris International reported record third-quarter 2026 results, with net revenues increasing 5.5% to $11.4 billion and adjusted diluted EPS growing 5.4% to $2.36. The company's smoke-free business now accounts for over 40% of total net revenues, supported by continued momentum in IQOS heat-not-burn products and resilient combustible segment performance.

Term
Q3 2026

“We delivered another excellent quarter, with growing total volumes, double-digit organic operating income growth and robust margin expansion.”

Jacek Olczak, Group CEO PMI

“With continued strong offtake momentum for our smoke-free brands and the exceptional results of our combustible business, we are in a strong position to continue delivering best-in-class performance, and firmly on track for a sixth consecutive year of volume growth.”

Jacek Olczak, Group CEO PMI
7:02 AM ET 8-K
Financial Results Healthcare Services Group Inc HCSG

Healthcare Services Group Financial Results

Healthcare Services Group reported Q3 2026 revenue of $479.6 million and net income of $24.9 million. The company also announced the $93.5 million acquisition of NEXDINE Hospitality and raised its 2027 revenue growth outlook to low double-digits.

Term
3 months

“Our strong third quarter results reflect the underlying strength of our business fundamentals and disciplined operational execution. The organic growth inflection we planned for, and are now delivering, sets the stage for fourth quarter revenue in the range of $535 to $545 million and low double-digit top-line growth in 2027.”

Ted Wahl, Chief Executive Officer

“Our acquisition of NEXDINE Hospitality in early October represents a significant milestone, deepening our health and hospitality services capabilities and unlocking new growth pathways in senior living and hospitality-driven markets.”

Ted Wahl, Chief Executive Officer
7:02 AM ET 8-K
Clinical Trial Data Genprex, Inc. GNPX

Genprex Clinical Trial Data

Genprex highlighted peer-reviewed preclinical research published in Mechanisms of Ageing and Development regarding the TUSC2 gene, which is the therapeutic component of its REQORSA oncology program. The study found that TUSC2 deficiency in mice leads to mitochondrial dysfunction and protein homeostasis collapse in the brain, with human datasets showing TUSC2 expression also declines with age and Alzheimer's disease. While exploratory, the findings suggest TUSC2 plays a foundational role in brain health beyond its established role in cancer treatment.

Counterparty
Meharry Medical College
7:00 AM ET 8-K
Financial Results Stifel Financial Corp SF

Stifel Financial Financial Results

Stifel Financial Corp. reported third quarter 2026 net revenues of $1.43 billion and record non-GAAP diluted EPS of $1.46, up 12% year-over-year. Performance was driven by record Global Wealth Management revenues and a 14% increase in asset management fees, while the company also repurchased $124 million of its common stock.

Term
3 months

“Stifel is on track for another record year, with year-to-date revenue of $4.3 billion up 9%, core earnings per share of $4.33 up 22%, and return on tangible common equity of 24.1%. The investments we’ve made in our business continued to drive operating efficiencies, as we delivered our highest ever third quarter earnings per share of $1.46, up 12% versus the prior year, on net revenue of $1.43 billion. I am optimistic about our outlook, as Stifel’s diversified business model, recurring revenue stream, and disciplined capital management position us to keep compounding value for shareholders.”

Ronald J. Kruszewski, Chairman and Chief Executive Officer
7:00 AM ET 8-K
Nasdaq/NYSE Compliance Notice Vivos Therapeutics, Inc. VVOS

Vivos Therapeutics Nasdaq/NYSE Compliance Notice

Vivos Therapeutics received a letter from Nasdaq confirming that the company has regained compliance with the minimum stockholders' equity requirement of $2.5 million under Listing Rule 5550(b)(1). The compliance was achieved following a transaction involving the issuance of Series C Convertible Preferred Stock, which is expected to increase stockholders' equity by more than $10 million. The company must continue to evidence compliance in its next periodic report to avoid potential delisting.

Counterparty
The Nasdaq Stock Market LLC
6:59 AM ET 8-K
Financial Results Moodys Corp MCO

Moodys Financial Results

Moody’s Corporation reported third quarter 2026 revenue of $2.0 billion, a 1% increase from the prior-year period, with diluted EPS rising 18% to $4.24. The company reaffirmed its full-year 2026 adjusted diluted EPS guidance of $16.50 to $17.00 and highlighted strong year-to-date free cash flow of $2.2 billion.

Term
Q3 2026

“Moody’s delivered another quarter of strong profitability and earnings growth, with disciplined execution and healthy cash generation amidst an increasingly complex operating environment. It’s in markets like these that our customers truly value our independent insights and connected intelligence.”

Rob Fauber, President and Chief Executive Officer, Moody’s Corporation
6:51 AM ET 8-K
Dividend Labcorp Holdings Inc. LH

Labcorp Holdings Dividend

Labcorp Holdings Inc. announced that its Board of Directors has declared a quarterly cash dividend of $0.72 per share of common stock. The dividend is payable on December 11, 2026, to stockholders of record as of November 24, 2026.

6:47 AM ET 8-K
Financial Results BankUnited, Inc. BKU

BankUnited Financial Results

BankUnited, Inc. reported Q3 2026 net income of $72.2 million and diluted EPS of $1.01, driven by net interest margin expansion to 3.16%. The company also highlighted improved credit trends and the repurchase of 2.1 million shares for $97.0 million during the quarter.

Term
Q3 2026

“We delivered another quarter of solid performance, with continued deposit momentum and net interest margin expanding to 3.16%, ahead of our guidance. Benefiting from a strong economy, we remain focused on increasing profitability and creating long-term shareholder value.”

Rajinder Singh, Chairman, President and Chief Executive Officer
6:46 AM ET 8-K
M&A Deal Apex Tech Acquisition Inc. TRAD

Apex Tech Acquisition Signs $3.5B M&A Deal with Korai Flix, Inc.

APEX Tech Acquisition Inc. (a SPAC) has entered into a definitive merger agreement to acquire Korai Flix, Inc., an AI-powered interactive online entertainment platform, in a deal valuing Korai at $3.5 billion on a pre-money equity basis. Upon closing, the combined entity will be renamed Krflix Group, Inc. and is expected to list on the NYSE. The transaction is projected to close in the first quarter of 2027, subject to shareholder and regulatory approvals.

Value
$3.5B
Counterparty
Korai Flix, Inc.
6:46 AM ET 8-K
M&A Deal Nova Minerals Corp NVA

Nova Minerals Signs $3.5B M&A Deal with Korai Flix Inc.

APEX Tech Acquisition Inc. (NYSE: TRAD) has entered into a definitive merger agreement to acquire Korai Flix Inc., an AI-powered interactive online entertainment platform, in a deal valuing Korai at $3.5 billion on a pre-money equity basis. Upon closing, expected in Q1 2027, the combined company will be renamed Krflix Group Inc. and is expected to list on the NYSE.

Value
$3.5B
Counterparty
Korai Flix Inc.
6:40 AM ET 8-K
Financial Results Northern Trust Corp NTRS

Northern Trust Financial Results

Northern Trust Corporation reported third quarter 2026 net income of $642.9 million, or $3.40 per diluted share, representing a 40% increase in net income compared to the prior-year quarter. Results were driven by an 8% year-over-year increase in trust fees and 13% growth in total revenue, partially offset by a 5% increase in noninterest expenses.

“Northern Trust delivered strong third-quarter results, demonstrating continued progress against our One Northern Trust strategy. Compared to the prior year and excluding notable items, revenues grew 11%, while disciplined expense management generated more than 600 basis points of positive operating leverage. As a result, pretax income increased 21% and earnings per share increased 40%.”

Michael O’Grady, Chairman and Chief Executive Officer
6:32 AM ET 8-K
Financial Results AT&T Inc. T

AT&T Financial Results

AT&T reported third-quarter 2026 results with consolidated revenues of $32.3 billion, up 5.3% year-over-year, driven by strong growth in Advanced Connectivity services. The company added over 1 million Advanced Connectivity customers for the second consecutive quarter and raised its full-year adjusted EPS guidance. AT&T remains on track to reach over 60 million fiber locations by the end of 2030.

Term
Q3 2026

“We are growing valuable customer relationships as more homes and businesses choose AT&T for all their advanced connectivity needs across both internet and on-the-go wireless. Our asset base positions us well for the AI era, with a leading position in fiber – the best technology available. We’re building the nation’s strongest network, backed by America’s Best Guarantee, to deliver faster, more reliable and more accessible connectivity.”

John Stankey, AT&T Chairman and CEO
6:15 AM ET 8-K
Financial Results Integra Lifesciences Holdings Corp IART

Integra Lifesciences Holdings Financial Results

Integra LifeSciences reported Q3 2026 revenues of $411.2 million, a 2.3% increase year-over-year, despite a $7 million impact from flood damage at its Cincinnati facility. The company achieved GAAP net income of $14.9 million ($0.19 per share) and adjusted EPS of $0.59, while generating $96 million in operating cash flow.

Term
Q3 2026

“Our third quarter performance reflected mixed results across our portfolio, with stronger performance in Specialty Surgery partially offset by a $7 million impact from the Cincinnati disruption and softer-than-expected results in Tissue Reconstruction. We delivered results within our guidance ranges, generated strong cash flow, reduced leverage, and subsequently completed our debt refinancing.”

Stuart Essig, Chairman and Chief Executive Officer

“Our updated outlook reflects both the recovery timeline in Cincinnati and more measured expectations for portions of our Tissue Reconstruction business. We are focused on executing against these challenges while continuing to support our customers, advance key product launches and returns, and strengthen the business for more consistent long-term growth.”

Stuart Essig, Chairman and Chief Executive Officer
6:05 AM ET 8-K
Financial Results Thermo Fisher Scientific Inc. TMO

Thermo Fisher Scientific Financial Results

Thermo Fisher Scientific reported third-quarter 2026 revenue of $12.14 billion, representing 9% growth (6% organic) compared to the prior year. The company achieved GAAP diluted EPS of $4.64 and adjusted EPS of $6.68, driven by its growth strategy and the PPI Business System.

Term
Q3 2026

“We are very pleased to deliver another excellent quarter, with outstanding financial performance on both the top and bottom line. We’re advancing our proven growth strategy, which is resonating strongly with our customers, and our PPI Business System is enabling outstanding execution across the company.”

Marc N. Casper, chairman and chief executive officer of Thermo Fisher Scientific

“Looking ahead, we’re well positioned to deliver an excellent 2026 as we continue to drive long-term value creation for all of our stakeholders and build an even brighter future for our company.”

Marc N. Casper, chairman and chief executive officer of Thermo Fisher Scientific
6:05 AM ET 8-K
M&A Deal Silicon Valley Acquisition Corp. SVAQ

Silicon Valley Acquisition Signs $5M M&A Deal with EigenQ, Inc.

Silicon Valley Acquisition Corp. (SVAQ) provided an update on its pending merger with EigenQ, Inc., specifically announcing a subordinated unsecured note financing. SVAQ and EigenQ entered into an agreement with an investor for the issuance of up to $5 million in promissory notes and warrants to support the transaction. This financing is part of the broader capital structure required to complete the previously announced business combination.

Value
$5M
Counterparty
EigenQ, Inc.
6:04 AM ET 8-K
M&A Deal Nuburu, Inc. BURU

Nuburu M&A Deal with Tekne S.p.A.

Nuburu, Inc. completed the acquisition of an additional 67.1% interest in Tekne S.p.A. for a fixed purchase price of €5.2 million, bringing its total ownership to 70%. The deal includes a €20 million cash earn-out payable through 2036 based on 5% of annual revenues with a guaranteed annual minimum of €2 million. As part of the transaction, Nuburu waived approximately €29.7 million in receivables owed by Tekne as a capital contribution to recapitalize the entity.

Counterparty
Tekne S.p.A.
Term
Earn-out through 2036
6:04 AM ET 8-K
Financial Results Elevance Health, Inc. ELV

Elevance Health Financial Results

Elevance Health reported Q3 2026 operating revenue of $50.4 billion and raised its full-year 2026 adjusted diluted EPS guidance to at least $29.00. The results were driven by improved operating performance in Medicare Advantage and Individual ACA, alongside growth in CarelonRx product revenue.

Term
Q3 2026

“Elevance Health's third quarter results reflect stronger execution across our diversified portfolio and underscore the earnings power of the business. We are raising our 2026 earnings outlook and remain confident in delivering at least 12% growth in adjusted diluted earnings per share in 2027 from our higher earnings baseline of at least $26.75. By bringing together the capabilities of our Health Benefits business and Carelon, we are improving the healthcare experience, strengthening our competitive advantage, and creating long-term value for our shareholders.”

Gail K. Boudreaux, President and Chief Executive Officer
6:04 AM ET 8-K
Executive Compensation reAlpha Tech Corp. AIRE

reAlpha Tech Executive Compensation

reAlpha Tech Corp. has approved an updated compensation policy for its non-executive directors. Each director will receive $100,000 in total annual compensation, split between $75,000 in common stock issued quarterly and $25,000 in cash.

6:04 AM ET Form 4
Insider Selling Sea Ltd SE

Sea CCO and GC Yanjun Wang Sells $137K of Stock

Yanjun Wang, CCO and GC, sold 1,581 shares of Sea Ltd at $80.76 to $90.29 a share (average $86.67) in 3 transactions, worth $137K in total between Oct 19, 2026 and Oct 20, 2026. Shares held after the trade: 76,157 (-0.2%).

Value
$137K
Shares
1,581
Average price
$86.67
Role
CCO and GC
Holding change
-0.2%
Trade date
Oct 19, 2026 to Oct 20, 2026
6:04 AM ET 8-K
Financial Results Artificial Intelligence Technology Solutions Inc. AITX

Artificial Intelligence Technology Solutions Financial Results

Artificial Intelligence Technology Solutions reported Q2 FY2027 revenue of $1.99 million, an 8% sequential increase driven by record growth from its non-anchor customer base. The company noted a significant diversification of its revenue mix, with its largest customer now representing only 18% of revenue compared to 46% a year ago. Management is implementing an expanded cost-reduction program targeting monthly operating cash breakeven by January 2027.

Term
Q2 FY2027
6:04 AM ET Form 4
Insider Selling Sea Ltd SE

Sea CFO Tianyu Hou Sells $885K of Stock

Tianyu Hou, CFO, sold 9,937 shares of Sea Ltd at $88.54 to $93.00 a share (average $89.01) in 5 transactions, worth $885K in total on Oct 19, 2026. Shares held after the trade: 35,000 (-0.5%).

Value
$885K
Shares
9,937
Average price
$89.01
Role
CFO
Holding change
-0.5%
Trade date
Oct 19, 2026
6:04 AM ET 8-K
Leadership Change Entravision Communications Corp EVC

Entravision Communications Leadership Change

Entravision appointed Brian Krzanich (former Intel CEO) and Gary Ferrera to its Board of Directors, effective October 14, 2026. Simultaneously, the company announced the resignation of Fehmi Zeko effective October 23, 2026, and that Gilbert Vasquez will not stand for re-election at the 2027 Annual Meeting.

6:04 AM ET 10-Q
Financial Results ClimateRock CLRCF

ClimateRock Q1 2026 Results: Net Loss of $168K, Loss Narrows

ClimateRock reported a net loss of $168,338 for the quarter ended March 31, 2026, compared to a net loss of $185,038 in the prior year period. The company remains a shell company with $162,356 held in its Trust Account and is actively seeking a business combination in the climate and renewable energy sectors.

Key figure
Net loss $168K
6:04 AM ET 10-Q
Financial Results ClimateRock CLRCF

ClimateRock Q2 2026 Results: Net Loss of $124K, Loss Narrows

ClimateRock reported a net loss of $292,815 for the six months ended June 30, 2026, as it continues its search for a business combination target. The company's total assets decreased to $108,638 from $166,608 at the end of 2025, primarily due to redemptions of Class A ordinary shares. As a shell company, its activities remain focused on formation, administrative compliance, and identifying a merger partner in the climate and renewable energy sectors.

Key figure
Net loss $124K
6:04 AM ET 8-K/A
Capital Raise Cenntro Inc. CENN

Cenntro Capital Raise

Cenntro Inc. filed an amendment to a previous 8-K to include a legal opinion from Wendot Law Group regarding its at-the-market (ATM) equity offering program. The filing serves as a routine administrative update to support the company's existing registration statement for the sale of common stock.

6:03 AM ET 8-K
M&A Deal Olenox Industries Inc. OLOX

Olenox Industries Signs $22M M&A Deal with IPD Industries, Inc. and Wildboy Holdings, Ltd.

Olenox Industries completed the acquisition of IPD Industries and Wildboy Holdings for $22 million in a mix of common stock, Series F preferred stock, and cash. The deal adds natural gas processing assets in British Columbia and a 100 MW power-development platform in Texas to support the company's gas-to-power-to-compute strategy for AI and data centers.

Value
$22M
Counterparty
IPD Industries, Inc. and Wildboy Holdings, Ltd.

“Power is becoming one of the defining constraints on the growth of artificial intelligence and digital infrastructure. With these acquisitions, we are building a platform that starts with the energy itself. Wildboy gives us control of natural gas resources, and IPD gives us a registered foundation for developing power generation in West Texas. Together, they position us to capture more value across the chain -- from gas to electricity to computing.”

Michael McLaren, Chairman and Chief Executive Officer of Olenox
6:03 AM ET 8-K
Other 8-K Filing Starry Sea Acquisition Corp SSEA

Starry Sea Acquisition Other 8-K Filing

Starry Sea Acquisition Corp (SSEA) shareholders approved an extension of the deadline to complete a business combination from November 7, 2026, to November 7, 2027. The company will deposit a monthly extension fee into its trust account equal to the lesser of $60,000 or $0.033 per public share for each one-month extension used. In connection with the vote, the company adopted its Third Amended and Restated Memorandum and Articles of Association.

Counterparty
Odyssey Transfer and Trust Company
Term
12 months
6:02 AM ET 8-K
Investor Presentation PDS Biotechnology Corp PDSB

PDS Biotechnology Investor Presentation

PDS Biotechnology updated its corporate presentation deck for October 2026, providing an overview of its oncology drug development programs. The presentation includes updates on its Versamune-based product candidates, including PDS0101 and PDS0301, and discusses the company's research and development strategy.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.